A Case Report of Consecutive Live Birth Twice Through in vitro Fertilization and Embryo Transfer After Endometrial Carcinoma Fertility Preservation Treatment

References

• Oaknin A, Bosse TJ, Creutzberg CL, et al. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(9):860–877. doi:10.1016/j.annonc.2022.05.009
   PubMed Web of Science ®Google Scholar
• Abu-Rustum N, Yashar C, Arend R, et al. Uterine neoplasms, version 1.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(2):181–209.
   PubMed Web of Science ®Google Scholar
• Pergialiotis V, Zachariou E, Vlachos DE, et al. Tumor free distance from serosa and survival rates of endometrial cancer patients: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2023;286:16–22. doi:10.1016/j.ejogrb.2023.05.001
   PubMed Web of Science ®Google Scholar
• Son J, Carr C, Yao M, et al. Endometrial cancer in young women: prognostic factors and treatment outcomes in women aged ≤40 years. Int J Gynecol Cancer. 2020;30(5):631–639. doi:10.1136/ijgc-2019-001105
   PubMed Web of Science ®Google Scholar
• Bourou MZ, Matsas A, Vrekoussis T, Mastorakos G, Valsamakis G, Panoskaltsis T. Conservative treatment of endometrial cancer in women of reproductive age (Review). Mol Clin Oncol. 2023;19(1):55. doi:10.3892/mco.2023.2651
   PubMed Web of Science ®Google Scholar
• Fan Z, Li H, Hu R, Liu Y, Liu X, Gu L. Fertility-preserving treatment in young women with grade 1 presumed stage IA endometrial adenocarcinoma: a meta-analysis. Int J Gynecol Cancer. 2018;28(2):385–393. doi:10.1097/IGC.0000000000001164
   PubMed Web of Science ®Google Scholar
• Quick CM, May T, Horowitz NS, Nucci MR. Low-grade, low-stage endometrioid endometrial adenocarcinoma: a clinicopathologic analysis of 324 cases focusing on frequency and pattern of myoinvasion. Int J Gynecol Pathol. 2012;31(4):337–343. doi:10.1097/PGP.0b013e31823ff422
   PubMed Web of Science ®Google Scholar
• Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Radiother Oncol. 2021;154:327–353. doi:10.1016/j.radonc.2020.11.018
   PubMed Web of Science ®Google Scholar
• Rodolakis A, Biliatis I, Morice P, et al. European Society of Gynecological Oncology Task Force for Fertility Preservation: clinical recommendations for fertility-sparing management in young endometrial cancer patients. Int J Gynecol Cancer. 2015;25(7):1258–1265. doi:10.1097/IGC.0000000000000493
   PubMed Web of Science ®Google Scholar
• Laganà AS, La Rosa VL, Rapisarda AM, Vitale SG. Comment on: “Needs and priorities of women with endometrial and cervical cancer”. J Psychosom Obstet Gynaecol. 2017;38(1):85–86. doi:10.1080/0167482X.2016.1244186
   PubMed Web of Science ®Google Scholar
• Park JY, Nam JH. Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer. Oncologist. 2015;20(3):270–278. doi:10.1634/theoncologist.2013-0445
   PubMed Web of Science ®Google Scholar
• Fukui Y, Taguchi A, Adachi K, et al. Polycystic ovarian morphology may be a positive prognostic factor in patients with endometrial cancer who achieved complete remission after fertility-sparing therapy with progestin. Asian Pac J Cancer Prev. 2017;18(11):3111–3116. doi:10.22034/APJCP.2017.18.11.3111
   PubMedGoogle Scholar
• Boardman L, Novetsky AP, Valea F. Management of endometrial intraepithelial neoplasia or atypical endometrial hyperplasia: ACOG Clinical Consensus No. 5. Obstet Gynecol. 2023;142(3):735–744. doi:10.1097/AOG.0000000000005297
   PubMed Web of Science ®Google Scholar
• Terzic M, Norton M, Terzic S, Bapayeva G, Aimagambetova G. Fertility preservation in endometrial cancer patients: options, challenges and perspectives. Ecancermedicalscience. 2020;14:1030.0. doi:10.3332/ecancer.2020.1030
   PubMed Web of Science ®Google Scholar
• Wang Y, Yang JX. Fertility-preserving treatment in women with early endometrial cancer: the Chinese experience. Cancer Manag Res. 2018;10:6803–6813. doi:10.2147/CMAR.S188087
   PubMed Web of Science ®Google Scholar
• Giampaolino P, Cafasso V, Boccia D, et al. Fertility-sparing approach in patients with endometrioid endometrial cancer grade 2 Stage IA (FIGO): a qualitative systematic review. Biomed Res Int. 2022;2022:4070368. doi:10.1155/2022/4070368
   PubMed Web of Science ®Google Scholar
• Wang F, Yu A, Xu H, et al. Fertility preserved hysteroscopic approach for the treatment of stage IA endometrioid carcinoma. Int J Gynecol Cancer. 2017;27(9):1919–1925. doi:10.1097/IGC.0000000000001109
   PubMed Web of Science ®Google Scholar
• Yuan F, Hu Y, Han X, Li Q, Hashmi MF. Metformin in combination with progesterone improves the pregnancy rate for patients with early endometrial cancer. Contrast Media Mol Imaging. 2022;2022:1961016. doi:10.1155/2022/1961016
   PubMed Web of Science ®Google Scholar
• Tai W, Hu L, Wen J. Maternal and neonatal outcomes after assisted reproductive technology: a retrospective cohort study in China. Front Med. 2022;9:837762. doi:10.3389/fmed.2022.837762
   Web of Science ®Google Scholar
• Gallos ID, Yap J, Rajkhowa M, Luesley DM, Coomarasamy A, Gupta JK. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2012;207(4):266.e1–266.12. doi:10.1016/j.ajog.2012.08.011
   PubMed Web of Science ®Google Scholar
• Park J-Y, Seong SJ, Kim T-J, et al. Pregnancy outcomes after fertility-sparing management in young women with early endometrial cancer. Obstet Gynecol. 2013;121(1):136–142. doi:10.1097/AOG.0b013e31827a0643
   PubMed Web of Science ®Google Scholar
• Inoue O, Hamatani T, Susumu N, et al. Factors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia. Reprod Biol Endocrinol. 2016;14(1):2. doi:10.1186/s12958-015-0136-7
   PubMedGoogle Scholar
• Siristatidis C, Sergentanis TN, Kanavidis P, et al. Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer--a systematic review and meta-analysis. Hum Reprod Update. 2013;19(2):105–123. doi:10.1093/humupd/dms051
   PubMed Web of Science ®Google Scholar
• Vaugon M, Peigné M, Phelippeau J, Gonthier C, Koskas M. IVF impact on the risk of recurrence of endometrial adenocarcinoma after fertility-sparing management. Reprod Biomed Online. 2021;43(3):495–502. doi:10.1016/j.rbmo.2021.06.007
   PubMed Web of Science ®Google Scholar
• Song Z, Liu H, Zhou R, et al. The optimal time for the initiation of in vitro fertilization and embryo transfer among women with atypical endometrial hyperplasia and endometrial carcinoma receiving fertility-sparing treatment. Arch Gynecol Obstet. 2022;305(5):1215–1223. doi:10.1007/s00404-021-06320-3
   PubMed Web of Science ®Google Scholar
• Qin Y, Yu Z, Yang J, et al. Oral progestin treatment for early-stage endometrial cancer: a systematic review and meta-analysis. Int J Gynecol Cancer. 2016;26(6):1081–1091. doi:10.1097/IGC.0000000000000723
   PubMed Web of Science ®Google Scholar
• Ronsini C, Mosca L, Iavarone I, et al. Oncological outcomes in fertility-sparing treatment in stage IA-G2 endometrial cancer. Front Oncol. 2022;12:965029. doi:10.3389/fonc.2022.965029
   PubMed Web of Science ®Google Scholar